NORTH TEXAS (CBSDFW.COM) — The Texas Department of State Health Services (DSHS) is allocating an initial shipment of an emergency treatment for COVID-19 to be distributed to acute care hospitals as early as next week.

The weekly shipments of bamlanivimab, the Eli Lilly & Company monoclonal antibody therapy, have been provided to the state at no cost through the U.S. Department of Health and Human Services.

READ MORE: Texas Sen. Ted Cruz Slams CDC's Updated Mask Guidance For Fully-Vaccinated People, Calls It A 'Mandate'

DSHS will allocate the initial distribution of bamlanivimab based on three criteria: new confirmed cases of COVID-19 in the community, new lab-confirmed COVID-19 admissions to hospitals, and total lab-confirmed COVID-19 patients in hospitals.

READ MORE: North Texas Pair Suspected Of Stealing $150K Motorhome Identified

“This initial allotment of bamlanivimab will help health care professionals effectively treat cases of COVID-19 within their communities and aid in reducing hospitalizations,” said Governor Greg Abbott.

Bamlanivimab is for outpatient use for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test. It has been shown to prevent hospitalizations in some patients if it is used before they become very sick.

MORE NEWS: Gov. Abbott Orders Texas National Guard To Help Make Arrests At Southern Border